Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PSMA antibody-drug conjugate ARX517

An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically conjugated to two of the microtubule-disrupting toxin amberstatin (AS269), with potential antineoplastic activity. Upon administration of anti-PSMA ADC ARX517, the monoclonal antibody moiety selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization, amberstatin binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of ARX517, increases payload stability and optimizes its efficacy.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC ARX517
anti-PSMA ADC ARX517
anti-PSMA/AS269 ADC ARX517
Code name:ARX 517
ARX-517
ARX517
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search